Strategic Trials to Define the Best Available Treatment for Neonatal and Pediatric Sepsis Caused by Carbapenem-resistant Organisms.

More search options...

Donà, D; Sharland, M; Heath, PT; Folgori, L (2019) Strategic Trials to Define the Best Available Treatment for Neonatal and Pediatric Sepsis Caused by Carbapenem-resistant Organisms. Pediatr Infect Dis J, 38 (8). pp. 825-827. ISSN 1532-0987 https://doi.org/10.1097/INF.0000000000002381
SGUL Authors: Sharland, Michael Roy Heath, Paul Trafford Folgori, Laura

Preview

PDF Accepted Version
Available under License Creative Commons Attribution Non-commercial.
Download (825kB) | Preview

Official URL: http://doi.org/10.1097/INF.0000000000002381

Abstract

The optimal standard of care for carbapenem-resistant bloodstream infections in children is currently unknown. This systematic review, aiming to define the best available treatments to be compared with new antibiotics in clinical trials, clearly points out the paucity of available data. The simplification and a wider harmonization of study design are a global priority to inform the best strategies to treat these life-threatening infections in children.

Item Type:

Article

Additional Information:

This is a non-final version of an article published in final form in Donà, D; Sharland, M; Heath, PT; Folgori, L (2019) Strategic Trials to Define the Best Available Treatment for Neonatal and Pediatric Sepsis Caused by Carbapenem-resistant Organisms. Pediatr Infect Dis J, 38 (8). pp. 825-827. ISSN 1532-0987 https://doi.org/10.1097/INF.0000000000002381

Keywords:

1114 Paediatrics And Reproductive Medicine, Pediatrics

SGUL Research Institute / Research Centre:

Academic Structure > Infection and Immunity Research Institute (INII)

Journal or Publication Title:

Pediatr Infect Dis J

ISSN:

1532-0987

Language:

eng

Dates: